Compare BIO-TECHNE Corp (TECH) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wolfspeed Inc — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Wolfspeed Inc trades at $31.75 (market cap $1.53B). The key difference: BIO-TECHNE Corp is far larger — about 7.3× Wolfspeed Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.
| TECH | WOLF | |
|---|---|---|
Market Cap | $11.16B | $1.53B |
Sector | Health | Technology |
52-Week High | $72.12 | $73.68 |
52-Week Low | $43.31 | $1.19 |
Enterprise Value | $11.24B | $2.19B |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
WOLF trades at $29.38, down 1.71% with bearish technical signals despite oversold RSI readings. The company shows negative profitability metrics with -79.83% net income margin and -14.54% ROE, though recent earnings beat expectations in two of three quarters. Strategic shifts toward data centers and defense markets alongside patent litigation activity create mixed sentiment.
Outlook remains challenging due to persistent losses and competitive pressures, though analyst consensus leans slightly bullish with 31.58% buy ratings. Key risks include execution on margin improvement and market share battles in the competitive semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
